23C6 reacts with the alpha V/beta 3 integrin (CD51/CD61). 23C6 may be useful for bone resorption modulation, osteoclast identification, receptor purification, malignant melanoma identification and treatment.
| Inventor | Institute |
|---|---|
| Mike Horton | Queen Mary University of London |
| Cat. #: | 151039 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Tissue-specific biology |
| Application: | FACS ; IHC ; IP ; Fn |
| Target: | Integrin alpha V B3 (CD51/61; Osteoclast Fn Antigen) |
| Reactivity: | Human |
| Clone: | 23C6 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038. |
| Product description: | 23C6 reacts with the alpha V/beta 3 integrin (CD51/CD61). 23C6 may be useful for bone resorption modulation, osteoclast identification, receptor purification, malignant melanoma identification and treatment. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 125/124 kDa, 150 kDa |
| Immunogen: | A cell suspension containing osteoclasts from osteoclastomas. |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha V associates with integrin beta3 to form the osteoclast Fn antigen (vitronectin receptor). Integrin alpha V is found in osteoclasts, placenta, melanoma cell lines and some epithelial cell lines. Expression of integrin alpha V increases with melanoma progression. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Chetty et al. 2010. Int J Cancer. 127(5):1081-95. PMID: 20027628. Martino et al. 2009. Biomaterials. 30(6):1089-97. PMID: 19027948. Zhou et al. 2006. J Exp Med. 203(4):1067-80. PMID: 16606672. Marshall et al. 1995. J Cell Sci. 108 ( Pt 3):1227-38. PMID: 7542669. Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.